Karolinska Institutet reveals an AI tool estimates brain age, showing a gap between chronological and biological ages in 70-year-olds. The study, signaling dementia risks, highlights vascular health's role in brain aging.

ARPA-H launches the PROSPR program to enhance Americans' healthspan, focusing on aging-related conditions and quality of life. The PATH project, with a $52 million budget, aims to utilize AI for personalized health strategies, potentially saving $29 billion annually.

The Founders Longevity Forum Singapore, slated for February 27-28, 2025, will spotlight innovations in longevity science and investment prospects. Organized by Founders Forum, NUS, and Longevity.Technology, it offers Precision Geromedicine and Longevity Investment tracks, featuring industry experts like Professor Andrea Maier and Phil Newman.

A study by the Robert N. Butler Columbia Aging Center shows older adults in England are healthier than past generations, with 70 becoming the new 60. Improvements are linked to better education, nutrition, and medical care, but rising obesity may threaten these gains.

The Corundum Convergence Institute has been launched to boost longevity research, emphasizing accessible, non-pharmaceutical interventions. Backed by Corundum Corp, CCI will support projects transitioning from academia to commercial use, with a request for proposals set for 2025 utilizing Human Phenotype Project data.

BioAge Labs teams up with Novartis in a $530 million research collaboration to study age-related diseases and exercise benefits. This follows BioAge's recent IPO and a halted obesity trial, underscoring both innovation and challenges in biotech.

A new review reveals that long-term exercise significantly improves cardiometabolic health in older individuals compared to their sedentary peers. However, these benefits do not fully offset age-related declines when compared to younger sedentary groups.

Vandria has begun a Phase 1 trial for VNA-318, a promising compound targeting age-related neurodegenerative diseases by enhancing mitophagy. With a US patent and strong preclinical results, Vandria aims to capture a significant share of the growing Alzheimer's therapy market, projected to expand to 12% CAGR by 2035.

BioAge Labs has teamed up with Novartis in a multi-year deal to target metabolic diseases linked to aging, leveraging BioAge's unique data and Novartis' expertise. The partnership, valued at up to $550 million, highlights the potential of combining proprietary discovery platforms with advanced analytics to identify new therapeutic targets, while both companies retain rights to further developments.

A study on Olympic gold medalists reveals that recent male champions show lower epigenetic age acceleration, while female champions display higher acceleration compared to non-champions. Differences in training, nutrition, and education may influence these epigenetic variations, suggesting that early, intense physical activity could impact longevity through changes in DNA methylation.

A study reveals taxi and ambulance drivers may have a reduced risk of Alzheimer's, possibly due to their navigational skills enhancing brain health. Experts highlight the need to explore how occupational demands could influence dementia risk, but caution against overstating these findings.

New research published in Aging shows that the senolytic compound ABT-263 accelerates wound healing in aged mice when applied before injury. The treatment enhances gene activity for healing, but also raises inflammation, indicating potential surgical benefits for older individuals, pending further human trials.

Fight Aging! newsletter explores breakthroughs in combating aging, focusing on topics like brain health and athletic longevity. It also offers insights into the complexities of aging and potential medical interventions.

XPRIZE Healthspan announces its largest-ever $101 million prize to drive advancements in healthspan and aging, attracting 510 teams from 54 countries. The competition, allowing late entries until 2027, aims to democratize longevity research, with a focus on collaboration between academic and corporate entities.

Neko Health leads the emerging longevity clinical services sector with AI-driven scans for preventive care and aging intervention. The industry's growth highlights the need for standardized protocols and offers investment opportunities in IT, wellness collaborations, and new therapies.

Buenavista Equity Partners, in collaboration with Columbus Venture Partners, has launched a €100 million healthcare fund with a target of €150 million. This fund, boosted by CDTI's €58 million commitment, aims to invest in up to 12 innovative healthcare companies, focusing on precision medicine and age-related diseases.

Will Harbone has unveiled LongGame, a $40 million venture fund aiming to extend human lifespans through biotechnology. The fund plans to invest in early-stage startups focusing on stem cell therapies, gene editing, and more, while integrating decentralized science for broader accessibility.

A JAMA Network Open study finds that despite increasing life expectancy, the U.S. faces a widening gap between lifespan and healthspan, with Americans living longer yet sicker lives. Researchers urge a shift toward wellness-focused healthcare to tackle chronic diseases and enhance life quality, noting the U.S. leads in years lived with disabilities.

A study in Neurology reveals older adults with varying blood pressure, notably Black participants, are at higher cognitive decline risk. The research emphasizes blood pressure management as a modifiable risk factor, though it lacks racial diversity beyond Black and white participants.